BR0010082A - Método para melhorar a eficácia de um agente antitumoral - Google Patents

Método para melhorar a eficácia de um agente antitumoral

Info

Publication number
BR0010082A
BR0010082A BR0010082-0A BR0010082A BR0010082A BR 0010082 A BR0010082 A BR 0010082A BR 0010082 A BR0010082 A BR 0010082A BR 0010082 A BR0010082 A BR 0010082A
Authority
BR
Brazil
Prior art keywords
effectiveness
improving
antitumor agent
agent
hematocrit
Prior art date
Application number
BR0010082-0A
Other languages
English (en)
Inventor
Steven M Piver
David F Silver
Original Assignee
Health Research Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Health Research Inc filed Critical Health Research Inc
Publication of BR0010082A publication Critical patent/BR0010082A/pt

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K33/00—Medicinal preparations containing inorganic active ingredients
    • A61K33/24—Heavy metals; Compounds thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/18—Growth factors; Growth regulators
    • A61K38/1816—Erythropoietin [EPO]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K33/00—Medicinal preparations containing inorganic active ingredients
    • A61K33/24—Heavy metals; Compounds thereof
    • A61K33/243—Platinum; Compounds thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Inorganic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Zoology (AREA)
  • Immunology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Peptides Or Proteins (AREA)
  • External Artificial Organs (AREA)

Abstract

"MéTODO PARA MELHORAR A EFICáCIA DE UM AGENTE ANTITUMORAL". é fornecido um método para intensificar o efeito de agentes anti-tumorais sobre tumores sólidos. O método compreende administrar a um paciente um agente anti-tumoral e um elevador hematócrito. O elevador hematócrito pode ser administrado antes ou simultaneamente com o agente anti-tumoral.
BR0010082-0A 1999-04-27 2000-04-24 Método para melhorar a eficácia de um agente antitumoral BR0010082A (pt)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US09/300,124 US6171620B1 (en) 1999-04-27 1999-04-27 Method of enhancing the efficacy of anti-tumor agents
PCT/US2000/011000 WO2000064455A1 (en) 1999-04-27 2000-04-24 Method of enhancing the efficacy of anti-tumor agents

Publications (1)

Publication Number Publication Date
BR0010082A true BR0010082A (pt) 2002-01-15

Family

ID=23157813

Family Applications (1)

Application Number Title Priority Date Filing Date
BR0010082-0A BR0010082A (pt) 1999-04-27 2000-04-24 Método para melhorar a eficácia de um agente antitumoral

Country Status (18)

Country Link
US (3) US6171620B1 (pt)
EP (1) EP1212068A4 (pt)
JP (1) JP2002542296A (pt)
KR (1) KR100693796B1 (pt)
CN (1) CN1188137C (pt)
AU (1) AU781301B2 (pt)
BG (1) BG64940B1 (pt)
BR (1) BR0010082A (pt)
CA (1) CA2368618C (pt)
HU (1) HUP0200840A3 (pt)
IL (1) IL146012A0 (pt)
MX (1) MXPA01010899A (pt)
NO (1) NO20015227L (pt)
NZ (1) NZ514521A (pt)
PL (1) PL350918A1 (pt)
RU (1) RU2271829C2 (pt)
WO (1) WO2000064455A1 (pt)
ZA (1) ZA200108012B (pt)

Families Citing this family (22)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7678391B2 (en) * 2000-04-26 2010-03-16 Queen's University At Kingston Formulations and methods of using nitric oxide mimetics against a malignant cell phenotype
US20050142217A1 (en) * 2000-04-26 2005-06-30 Adams Michael A. Formulations and methods of using nitric oxide mimetics against a malignant cell phenotype
AU2001250221B2 (en) 2000-04-26 2006-07-06 Queen's University At Kingston Formulations and methods of using nitric oxide mimetics against a malignant cell phenotype
CA2498319A1 (en) * 2002-09-09 2004-03-18 Nautilus Biotech Rational evolution of cytokines for higher stability, the cytokines and encoding nucleic acid molecules
EP1615646B2 (en) 2003-04-08 2022-07-27 Progenics Pharmaceuticals, Inc. Pharmaceutical formulations containing methylnaltrexone
DE10361813A1 (de) * 2003-12-30 2005-09-08 Bionethos Holding Gmbh Verfahren zur Regeneration von Gewebe
US8518962B2 (en) 2005-03-07 2013-08-27 The University Of Chicago Use of opioid antagonists
US8524731B2 (en) 2005-03-07 2013-09-03 The University Of Chicago Use of opioid antagonists to attenuate endothelial cell proliferation and migration
JP5241484B2 (ja) * 2005-03-07 2013-07-17 ザ ユニヴァーシティー オヴ シカゴ 内皮細胞増殖及び内皮細胞遊走を減弱するためのオピオイドアンタゴニストの使用
US9662325B2 (en) 2005-03-07 2017-05-30 The University Of Chicago Use of opioid antagonists to attenuate endothelial cell proliferation and migration
AR057035A1 (es) 2005-05-25 2007-11-14 Progenics Pharm Inc SíNTESIS DE (R)-N-METILNALTREXONA, COMPOSICIONES FARMACÉUTICAS Y USOS
AR057325A1 (es) 2005-05-25 2007-11-28 Progenics Pharm Inc Sintesis de (s)-n-metilnaltrexona, composiciones farmaceuticas y usos
JP2010510794A (ja) 2006-11-28 2010-04-08 ハナル ファーマシューティカル カンパニー リミテッド 修飾型エリスロポエチンポリペプチド及びこの治療用用途
AU2008233133B2 (en) 2007-03-29 2014-03-27 Progenics Pharmaceuticals, Inc. Crystal forms of (R) -N-methylnaltrexone bromide and uses thereof
TWI553009B (zh) 2007-03-29 2016-10-11 普吉尼製藥公司 末梢性類鴉片受體拮抗劑及其用途
PL2565195T3 (pl) 2007-03-29 2015-10-30 Wyeth Llc Obwodowy receptor opioidowy i jego antagoniści oraz ich zastosowania
KR101581480B1 (ko) 2008-02-06 2015-12-30 프로제닉스 파머슈티컬스, 인코포레이티드 (ｒ),(ｒ)-2,2'-비스-메틸날트렉손의 제조법 및 용도
US8685995B2 (en) 2008-03-21 2014-04-01 The University Of Chicago Treatment with opioid antagonists and mTOR inhibitors
CA2723621A1 (en) * 2008-05-15 2009-11-19 Edison Pharmaceuticals, Inc Treatment of hearing and balance impairments using compounds having erythropoietin activity
CA2676881C (en) 2008-09-30 2017-04-25 Wyeth Peripheral opioid receptor antagonists and uses thereof
PL230756B1 (pl) * 2015-09-11 2018-12-31 Univ Medyczny W Bialymstoku Erytropoetyna oraz inhibitor kinazy Brutona w postaci 2- cyjan o-N-( 2,5-dibromofenylo)- 3-hydroksy-2- butenamidu do zastosowania jako lek oraz ich zastosowanie do wytwarzania leku do terapii nowotworu
WO2019083023A1 (ja) * 2017-10-26 2019-05-02 国立大学法人筑波大学 癌の治療に使用するための組成物

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4745099A (en) * 1985-02-06 1988-05-17 Chugai Seiyaku Kabushiki Kaisha Pharmaceutical composition for the treatment of the anemia of malignant tumors
JP2632014B2 (ja) * 1988-03-03 1997-07-16 中外製薬株式会社 骨髄機能障害性貧血治療剤
JPH1067678A (ja) * 1996-06-20 1998-03-10 Chugai Pharmaceut Co Ltd 肝疾患治療用医薬組成物
US20020052309A1 (en) * 1996-09-11 2002-05-02 Athanasius A. Anagnostou Method of treating endothelial injury

Also Published As

Publication number Publication date
US20010000730A1 (en) 2001-05-03
ZA200108012B (en) 2003-03-26
BG106057A (en) 2002-04-30
NZ514521A (en) 2003-07-25
AU781301B2 (en) 2005-05-12
KR20020000557A (ko) 2002-01-05
EP1212068A1 (en) 2002-06-12
AU4486300A (en) 2000-11-10
PL350918A1 (en) 2003-02-10
HUP0200840A3 (en) 2003-04-28
IL146012A0 (en) 2002-07-25
US6426094B2 (en) 2002-07-30
CA2368618C (en) 2011-03-01
KR100693796B1 (ko) 2007-03-12
HUP0200840A2 (hu) 2002-07-29
MXPA01010899A (es) 2003-06-24
JP2002542296A (ja) 2002-12-10
US20020198153A1 (en) 2002-12-26
RU2271829C2 (ru) 2006-03-20
CN1188137C (zh) 2005-02-09
WO2000064455A1 (en) 2000-11-02
CN1352561A (zh) 2002-06-05
EP1212068A4 (en) 2007-03-14
US6171620B1 (en) 2001-01-09
US6620779B2 (en) 2003-09-16
CA2368618A1 (en) 2000-11-02
BG64940B1 (bg) 2006-10-31
NO20015227D0 (no) 2001-10-25
NO20015227L (no) 2001-12-27

Similar Documents

Publication Publication Date Title
BR0010082A (pt) Método para melhorar a eficácia de um agente antitumoral
FI19991893A (fi) Säädellysti budesonidia vapauttava oraalisesti annettava koostumus ja budesonidin käyttö
AR026165A1 (es) Dispositivo para la administracion de drogas.
BR0009016A (pt) Composição de apomorfina e sildenafil
ATE319447T1 (de) Pharmazeutische zubereitungen die clavulansäure oder derivate enthalten zur behandlund von neurologischen störungen
BR9911076A (pt) Uso de peg-ifn-alfa e ribavirina para o tratamento de hepatite c crÈnica
ES2162393T3 (es) Terapia de combinacion para erradicar el hcv-rna detectable en pacientes con infeccion de hepatitis c cronica.
AR021226A1 (es) Terapia combinatoria con ribavirina-interferon alfa para erradicar el hcv-rna detectable en aquellos pacientes que presentan infeccion porhepatitis c cronica
BR0115162A (pt) Tratamentos antitumorais eficazes
TR200103819T2 (tr) kanser tedavisinde ET743 terkipleri ve kullanımları
BR9916860A (pt) Método de reduzir colesterol do sangue e/outriglicerìdios do sangue em um indivìduo mamìfero,preparação em forma de unidade de dosagem, e,conjunto para administrar oralmente a mesma
WO2003049694A3 (en) Methods of therapy for non-hodgkin's lymphoma
TR200002969T2 (tr) Farmasötik bileşim.
AR015744A1 (es) Uso de dexmedetomidina para sedacion en terapia intensiva
EE200100066A (et) Naatriumkloriidi kasutamine kamptotetsiini derivaatide manustamisest tingitud gastrointestinaalsetekõrvaltoimete vähendamiseks
BR0009875A (pt) Uso de n-acetilcisteìna para a preparação de um medicamento adequado para a administração intravenosa para prevenir a carga oxidativa em pacientes que sofreram diálise
KR870010871A (ko) 재조합 인체 알파 인터페론에 의한 기저세포 암종의 병소내적 치료방법
DK0593562T3 (da) Topisk præparat indeholdende penciclovir
IT1291895B1 (it) Preparazione farmaceutica fluida a base di nimesulide per uso orale e rinofaringeo
DE60130253D1 (de) Zusammensetzungen zur verhinderung der adhäsion
EP1374873B8 (en) The use of n-acetyl-d-glucosamine in the manufacture of pharmaceutical useful for supressing side-effect of radiotherapy and chemotherapy
SE9700617D0 (sv) New composition
RU94024337A (ru) Антиметастатическое средство
AU4918900A (en) Interferon-beta use in the treatment of ewing's family of tumors
BR9810930A (pt) Composições farmacêuticas de arglabina e derivados de arglabina

Legal Events

Date Code Title Description
B07A Application suspended after technical examination (opinion) [chapter 7.1 patent gazette]
B09B Patent application refused [chapter 9.2 patent gazette]

Free format text: INDEFIRO O PEDIDO DE ACORDO COM O(S) ARTIGO(S) 8O, 13, 24 E 25 DA LPI.

B09B Patent application refused [chapter 9.2 patent gazette]

Free format text: MANTIDO O INDEFERIMENTO UMA VEZ QUE NAO FOI APRESENTADO RECURSO DENTRO DO PRAZO LEGAL.